PTEN regulates PDGF ligand switch for Î²-PDGFR signaling in prostate cancer.
Am. J. Pathol., Mar;180(3):1017-27 (2012)
Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration.
Cancer Res., Jul;70(13):5558-66 (2010)
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells.
Stem Cells., Jun;26(6):1425-35 (2008)
Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
Neoplasia., May;10(5):439-49 (2008)
C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis.
Neoplasia., Sep;10(9):996-1003 (2008)
CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.
Mol. Cancer Res., Mar;6(3):446-57 (2008)
Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner.
Int. J. Cancer., Jun;122(11):2482-90 (2008)
Lycopene and soy isoflavones in the treatment of prostate cancer.
Nutr Cancer., 59(1):1-7 (2007)
Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis.
Urol. Oncol., 25(5):407-11 (2007)
Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.
Am. J. Pathol., Jun;170(6):2100-11 (2007)
Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis.
Clin. Exp. Metastasis., 23(7-8):335-44 (2006)
Heterogeneous activation of MMP-9 due to prostate cancer-bone interaction.
Urology., Apr;69(4):795-9 (2007)
Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor.
Int. J. Cancer., Jun;118(11):2721-6 (2006)
Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Cancer Res., Apr;66(8):4173-81 (2006)
Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
Cancer Res., May;66(9):4816-25 (2006)
Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section.
Am. J. Pathol., May;168(5):1405-12 (2006)
Quantitative assessment of small intraosseous prostate cancer burden in SCID mice using fluorescence imaging.
Prostate., Jan;67(1):107-14 (2007)
High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy.
Urol. Oncol., 23(2):87-92 (2005)
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.
Prostate., Jan;66(1):32-48 (2006)
Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.
Neoplasia., Mar;7(3):207-23 (2005)